Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Inflammatory Bowel Diseases

Free Subscription Articles published in Lancet Gastroenterol Hepatol Retrieve available abstracts of 100 articles: HTML format

Single Articles

November 2025
1. SHEBAB M, Al-Hindawi A, Goodwin SW, Yuan Y, et al
   Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease.
   Lancet Gastroenterol Hepatol. 2025 Nov 25:S2468-1253(25)00346.
   PubMed    
   
   
   
2. VUIJK SA, Boute EH, de Ridder L
   Expanding the therapeutic arsenal for paediatric ulcerative colitis.
   Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00234.
   PubMed    
   
   
   
3. KAPLAN JL, Bousvaros A, Turner D, Dubinsky M, et al
   Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.
   Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00196.
   PubMed     Abstract available
   
   
   
4. DE BOER NK, Gearry RB, Bernstein CN, Banerjee R, et al
   The essential medicines list for inflammatory bowel disease: time to raise the standards of global care.
   Lancet Gastroenterol Hepatol. 2025 Nov 17:S2468-1253(25)00299.
   PubMed    
   
   
   
5. JAIRATH V, Danese S, D'Haens GR, Feagan BG, et al
   Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
   Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00296.
   PubMed     Abstract available
   
   
   
6. ATREYA R, Neurath MF
   Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis.
   Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00330.
   PubMed    
   
   
   
7. LI YIM AYF, Levin E, de Jonge WJ, Henneman P, et al
   Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease - Authors' reply.
   Lancet Gastroenterol Hepatol. 2025;10:973-974.
   PubMed    
   
   
   
8. LI H, Zeng J, Zhang L, Guo Q, et al
   Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease.
   Lancet Gastroenterol Hepatol. 2025;10:972-973.
   PubMed    
   
   
   October 2025
9. EGGERMONT E, Gecse K, Krugliak Cleveland N, Petersen F, et al
   Ulcerative colitis: moving beyond the mucosal dogma.
   Lancet Gastroenterol Hepatol. 2025 Oct 28:S2468-1253(25)00263.
   PubMed     Abstract available
   
   
   
10. HOIVIK ML
    Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00258.
    PubMed    
    
    
    
11. D'HAENS GR, Lowenberg M, Baert F, Bossuyt P, et al
    Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00233.
    PubMed     Abstract available
    
    
    September 2025
12. WU K, Zheng C, Cao Q, Ding Y, et al
    Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
    Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198.
    PubMed     Abstract available
    
    
    
13. VISSER E, Buskens CJ
    Appendicectomy for ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:789-790.
    PubMed    
    
    
    
14. SCARPA M, Castagliuolo I, Kotsafti A, Angriman I, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788.
    PubMed    
    
    
    
15. BRONZE S, Agrawal M, Rodriguez-Lago I, Colombel JF, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788-789.
    PubMed    
    
    
    July 2025
16. DANESE S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, et al
    Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
    Lancet Gastroenterol Hepatol. 2025 Jul 21:S2468-1253(25)00129.
    PubMed     Abstract available
    
    
    
17. YOGAKANTHI S, Raine T
    Progress in validation of treatment-response biomarkers in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00138.
    PubMed    
    
    
    
18. JOUSTRA VW, Li Yim AYF, Henneman P, Hageman I, et al
    Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00102.
    PubMed     Abstract available
    
    
    June 2025
19. BOUHNIK Y, Mary JY
    A new endoscopic paradigm: evaluating the EASE-CD score for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00127.
    PubMed    
    
    
    
20. MA C, Khanna R, Maguire BR, Zou G, et al
    Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00093.
    PubMed     Abstract available
    
    
    
21. PANACCIONE R, Vermeire S, Danese S, Higgins PDR, et al
    Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
    Lancet Gastroenterol Hepatol. 2025;10:507-519.
    PubMed     Abstract available
    
    
    
22. NOOR NM, Parkes M, Raine T
    U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:492-493.
    PubMed    
    
    
    
23. NEURATH MF, Artis D, Becker C
    The intestinal barrier: a pivotal role in health, inflammation, and cancer.
    Lancet Gastroenterol Hepatol. 2025;10:573-592.
    PubMed     Abstract available
    
    
    May 2025
24. FEAGAN BG, Sands BE, Siegel CA, Dubinsky MC, et al
    Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00071.
    PubMed     Abstract available
    
    
    
25. LINDSAY J
    Tulisokibart shows promise for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00103.
    PubMed    
    
    
    April 2025
26. HANNA LN, Munster LJ, Joshi S, Wendelien van der Bilt JD, et al
    Isolated perianal Crohn's disease: a systematic review and expert consensus proposing novel diagnostic criteria and management advice.
    Lancet Gastroenterol Hepatol. 2025 Apr 29:S2468-1253(25)00007.
    PubMed     Abstract available
    
    
    
27. UKASHI O, Ben-Horin S
    Appendicectomy: a novel treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00065.
    PubMed    
    
    
    
28. 
    Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00026.
    PubMed     Abstract available
    
    
    
29. HONAP S, Agrinier N, Torres J, Croitoru K, et al
    Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design.
    Lancet Gastroenterol Hepatol. 2025 Apr 2:S2468-1253(24)00439.
    PubMed     Abstract available
    
    
    March 2025
30. SHENOY S, Jena A, Levinson C, Sharma V, et al
    Inflammatory bowel disease in south Asia: a scoping review.
    Lancet Gastroenterol Hepatol. 2025;10:259-274.
    PubMed     Abstract available
    
    
    
31. D'HAENS G
    Vedolizumab for prevention of recurrence of Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:194-195.
    PubMed    
    
    
    
32. HAMMOUDI N, Allez M
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193.
    PubMed    
    
    
    
33. NGUYEN A, Li Wai Suen CFD, Srinivasan A, Segal J, et al
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193-194.
    PubMed    
    
    
    February 2025
34. TEMIDO MJ, Honap S, Jairath V, Vermeire S, et al
    Overcoming the challenges of overtreating and undertreating inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2025 Feb 4:S2468-1253(24)00355.
    PubMed     Abstract available
    
    
    
35. NOOR NM, Estevinho MM, Solitano V, Yuan Y, et al
    Applying the estimand framework to inflammatory bowel disease clinical trials.
    Lancet Gastroenterol Hepatol. 2025 Feb 3:S2468-1253(25)00004.
    PubMed    
    
    
    January 2025
36. SANDS BE, Panaccione R, D'Haens G, Schreiber S, et al
    Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00386.
    PubMed     Abstract available
    
    
    
37. ATREYA R, Neurath MF
    No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00397.
    PubMed    
    
    
    
38. ATIA O, Shavit-Brunschwig Z, Lev-Tzion R, Stein R, et al
    Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.
    Lancet Gastroenterol Hepatol. 2025 Jan 6:S2468-1253(24)00319.
    PubMed     Abstract available
    
    
    
39. LI WAI SUEN CFD, Choy MC, Con D, De Cruz P, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:19.
    PubMed    
    
    
    
40. HOFFERT Y, Ferrante M, Verstockt B, Dreesen E, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:18-19.
    PubMed    
    
    
    
41. COMAN D, Battat R
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:17-18.
    PubMed    
    
    
    
42. VAN DER DOES DE WILLEBOIS EML, Bemelman WA, Buskens CJ
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:16-17.
    PubMed    
    
    
    
43. COFFEY JC, Li Y, Walsh D, Connelly TM, et al
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15.
    PubMed    
    
    
    
44. KELM M, Flemming S
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15-16.
    PubMed    
    
    
    
45. DUAN M, Li Y
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14-15.
    PubMed    
    
    
    
46. YADAV A
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14.
    PubMed    
    
    
    December 2024
47. AINSWORTH MA
    Does filgotinib work for Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00304.
    PubMed    
    
    
    
48. VERMEIRE S, Schreiber S, Rubin DT, D'Haens G, et al
    Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00272.
    PubMed     Abstract available
    
    
    November 2024
49. D'HAENS G, Taxonera C, Lopez-Sanroman A, Nos P, et al
    Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00317.
    PubMed     Abstract available
    
    
    
50. MULLIGAN RJ, Lamb CA
    Vedolizumab prophylaxis against postoperative Crohn's disease recurrence.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00352.
    PubMed    
    
    
    
51. ANDERSEN V, Pingel J, Sofelt HL, Hikmat Z, et al
    Sex and gender in inflammatory bowel disease outcomes and research.
    Lancet Gastroenterol Hepatol. 2024;9:1041-1051.
    PubMed     Abstract available
    
    
    
52. GOMOLLON F
    Do placebos harm patients in IBD trials?
    Lancet Gastroenterol Hepatol. 2024;9:970-972.
    PubMed    
    
    
    October 2024
53. LU C, Rosentreter R, Parker CE, Remillard J, et al
    International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement.
    Lancet Gastroenterol Hepatol. 2024 Oct 21:S2468-1253(24)00265.
    PubMed     Abstract available
    
    
    September 2024
54. GROS B, Blackwell J, Segal J, Black CJ, et al
    Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00233.
    PubMed     Abstract available
    
    
    
55. DIN S, Segal J, Blackwell J, Gros B, et al
    Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00264.
    PubMed     Abstract available
    
    
    
56. KEDIA S, Ahuja V
    Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00229.
    PubMed    
    
    
    
57. CHOY MC, Li Wai Suen CFD, Con D, Boyd K, et al
    Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00200.
    PubMed     Abstract available
    
    
    July 2024
58. NOOR NM, Sebastian S, Parkes M, Raine T, et al
    The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 Jul 30:S2468-1253(24)00225.
    PubMed    
    
    
    
59. VAN DER DOES DE WILLEBOIS EML, Bellato V, Duijvestein M, van der Bilt JDW, et al
    Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00097.
    PubMed     Abstract available
    
    
    
60. CLICK B, Holubar SD
    Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand?
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00186.
    PubMed    
    
    
    
61. CHEN R, Zhang S
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:592.
    PubMed    
    
    
    
62. NOOR NM, Lee JC, Bond S, Parkes M, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial - Authors' reply.
    Lancet Gastroenterol Hepatol. 2024;9:592-594.
    PubMed    
    
    
    
63. BORKAR V, Lunagariya Y, Chopra S, Sasikumar D, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591.
    PubMed    
    
    
    
64. SATSANGI J, Nowak J, Kalla R, Colombel JF, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591-592.
    PubMed    
    
    
    
65. BOURGONJE AR, Visschedijk MC, Festen EAM, Weersma RK, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:590-591.
    PubMed    
    
    
    June 2024
66. GUPTA A, Guisado D, Ricart E, Colombel JF, et al
    Haematopoietic stem-cell transplantation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024;9:499-500.
    PubMed    
    
    
    May 2024
67. IACUCCI M, Santacroce G, Zammarchi I, Maeda Y, et al
    Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 May 14:S2468-1253(24)00053.
    PubMed     Abstract available
    
    
    
68. BETHLEHEM L, Estevinho MM, Grinspan A, Magro F, et al
    Microbiota therapeutics for inflammatory bowel disease: the way forward.
    Lancet Gastroenterol Hepatol. 2024;9:476-486.
    PubMed     Abstract available
    
    
    
69. FUMERY M, Buisson A
    Has the time come for a systematic top-down approach in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024;9:394-395.
    PubMed    
    
    
    April 2024
70. PARKES GC, Hedin CRH
    PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00088.
    PubMed    
    
    
    
71. CHANCHLANI N, Lin S, Bewshea C, Hamilton B, et al
    Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044.
    PubMed     Abstract available
    
    
    March 2024
72. BALDERRAMO D, Quaresma AB, Olivera PA, Savio MC, et al
    Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America.
    Lancet Gastroenterol Hepatol. 2024;9:263-272.
    PubMed     Abstract available
    
    
    
73. RIVIERE P, Li Wai Suen C, Chaparro M, De Cruz P, et al
    Acute severe ulcerative colitis management: unanswered questions and latest insights.
    Lancet Gastroenterol Hepatol. 2024;9:251-262.
    PubMed     Abstract available
    
    
    February 2024
74. CHAPMAN TP, Ahmad T, Satsangi J
    Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
    Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
    PubMed    
    
    
    
75. NOOR NM, Lee JC, Bond S, Dowling F, et al
    A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
    PubMed     Abstract available
    
    
    
76. CICCOCIOPPO R, Gaspar L
    Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere.
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(24)00004.
    PubMed    
    
    
    
77. LINDSAY JO, Hind D, Swaby L, Berntsson H, et al
    Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, ra
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(23)00460.
    PubMed     Abstract available
    
    
    January 2024
78. SEBASTIAN S, Siegmund B, Teferra F, McGovern DPB, et al
    Promoting equity in inflammatory bowel disease: a global approach to care.
    Lancet Gastroenterol Hepatol. 2024 Jan 11:S2468-1253(23)00368.
    PubMed    
    
    
    December 2023
79. FUMERY M, Buisson A
    Guselkumab in Crohn's disease: the IL-23 race continues.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00356.
    PubMed    
    
    
    
80. DANESE S, Panaccione R, Feagan BG, Afzali A, et al
    Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318.
    PubMed     Abstract available
    
    
    October 2023
81. DIBLEY L, Duffy M
    Inflammatory bowel disease health care for LGTBQIA+ patients.
    Lancet Gastroenterol Hepatol. 2023 Oct 20:S2468-1253(23)00352.
    PubMed    
    
    
    
82. PATHIYIL MM, Jena A, Venkataramana Raju AK, Omprakash TA, et al
    Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2023 Oct 10:S2468-1253(23)00193.
    PubMed     Abstract available
    
    
    
83. QUAN J, Markovinovic A, Hracs L, Ma C, et al
    Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
    PubMed    
    
    
    September 2023
84. VERMEIRE S, Danese S, Zhou W, Ilo D, et al
    Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-bl
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208.
    PubMed     Abstract available
    
    
    
85. ATREYA R, Neurath MF
    Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00271.
    PubMed    
    
    
    August 2023
86. SENIOR K
    Surgery in Crohn's disease: patients need MDT-led holistic care.
    Lancet Gastroenterol Hepatol. 2023 Aug 8:S2468-1253(23)00274.
    PubMed    
    
    
    
87. SHIN A
    Psychological therapies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00229.
    PubMed    
    
    
    
88. RIGGOTT C, Mikocka-Walus A, Gracie DJ, Ford AC, et al
    Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00186.
    PubMed     Abstract available
    
    
    July 2023
89. PARIGI TL, D'Amico F, Abreu MT, Dignass A, et al
    Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
    Lancet Gastroenterol Hepatol. 2023 Jul 6:S2468-1253(23)00154.
    PubMed     Abstract available
    
    
    May 2023
90. JULSGAARD M, Mahadevan U, Vestergaard T, Mols R, et al
    Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 May 31:S2468-1253(23)00158.
    PubMed    
    
    
    
91. JAGT JZ, van Rheenen PF, Thoma SMA, Gower J, et al
    The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership.
    Lancet Gastroenterol Hepatol. 2023 May 22:S2468-1253(23)00140.
    PubMed    
    
    
    
92. JENA A, Sharma V, Sebastian S
    Reducing disparities in training in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 May 10:S2468-1253(23)00105.
    PubMed    
    
    
    
93. BRIERLEY R
    18th Congress of the European Crohn's and Colitis Organisation.
    Lancet Gastroenterol Hepatol. 2023;8:404.
    PubMed    
    
    
    
94. LOUIS E
    Treatment de-escalation in Crohn's disease - Author's reply.
    Lancet Gastroenterol Hepatol. 2023;8:401-402.
    PubMed    
    
    
    
95. MCSHANE C, Kevans D
    Treatment de-escalation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023;8:401.
    PubMed    
    
    
    
96. THE LANCET GASTROENTEROLOGY HE
    The economic burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023;8:391.
    PubMed    
    
    
    April 2023
97. SINGH S, Boland BS, Jess T, Moore AA, et al
    Management of inflammatory bowel diseases in older adults.
    Lancet Gastroenterol Hepatol. 2023;8:368-382.
    PubMed     Abstract available
    
    
    March 2023
98. MASSIRONI S, Vigano C, Palermo A, Pirola L, et al
    Inflammation and malnutrition in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Mar 15:S2468-1253(23)00011.
    PubMed     Abstract available
    
    
    
99. BANERJEE R, Raghunathan N, Pal P
    Managing inflammatory bowel disease: what to do when the best is unaffordable?
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00062.
    PubMed    
    
    
    
100. BURISCH J, Zhao M, Odes S, De Cruz P, et al
     The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
     Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00003.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.